IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers — Stella
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(15 sites)
France
Institut de Cancerologie de l'Ouest , medical oncology department, Angers
Institut Bergonié, medical oncology department, Bordeaux
Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital, Bron
Centre Hospitalier Universitaire de Lille, medical oncology department, Lille
Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital, Lyon
AP-HM, TIMONE Hospital, medical oncology department, Marseille
Institut Paoli-Calmettes Marseille, medical oncology department, Marseille
Institut Régional du Cancer de Montpellier, medical oncology department, Montpellier
Institut Curie, thoracic oncology department, Paris
AP-HP, Tenon Hospital, medical oncology department, Paris
Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital, Pierre-Bénite
Centre Eugène Marquis, medical oncology department, Rennes
Insitut de Cancérologie Strasbourg Europe, medical oncology department, Strasbourg
ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department, Toulouse
Institut Gustave Roussy, medical oncology department, Villejuif